Neurolixis places high priority on publishing data on its drug development candidates (NLX-112 and NLX-101) and its drug discovery program in reputable peer-reviewed science journals. To view over 50 articles on NLX-112 and NLX-101 see the complete list of publications on PubMed (from US National Library of Medicine). For abstracts of selected publications see the links below.
Note: NLX-112 was previously known as F13640 (befiradol) and NLX-101 was previously known as F15599.

 

Selected Publications on NLX-112:

 

The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques.
Depoortere R, Johnston TH, Fox SH, Brotchie JM, Newman-Tancredi A.
Parkinsonism Relat Disord. 2020 Aug 13;78:151-157. doi: 10.1016/j.parkreldis.2020.08.009. 
 
The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets.
Fisher R, Hikima A, Morris R, Jackson MJ, Rose S, Varney MA, Depoortere R, Newman-Tancredi A.
Neuropharmacology. 2020 May 1;167:107997. doi: 10.1016/j.neuropharm.2020.107997. 

 

Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT1A receptor agonist

Newman-Tancredi A, Martel J-C, Cosi C, Heusler P, Lestienne F, Varney MA, Cussac D.
Journal of Pharmacy and Pharmacology, 2017 June 14. DOI: 10.1111/jphp.12762

 

The novel 5-HT1A receptor agonist, NLX-112, reduces L-DOPA-induced abnormal involuntary movements in rat: a chronic administration study with microdialysis measurements.

McCreary AC, Varney MA, Newman-Tancredi A
Neuropharmacology. 2016 Jan 8. pii: S0028-3908(16)30013-2. doi: 10.1016/j.neuropharm.2016.01.013.

 

NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.

Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, Depoortère R, Cenci MA, Newman-Tancredi A
Exp Neurol. 2015 May 30. doi: 10.1016/j.expneurol.2015.05.021

 

 

Selected Publications on NLX-101:

 

Cortical 5-hydroxytryptamine 1A receptor biased agonist, NLX-101, displays rapid-acting antidepressant-like properties in the rat chronic mild stress model.

Depoortère R, Papp M, Gruca P, Lason-Tyburkiewicz M, Niemczyk M, Varney MA, Newman-Tancredi A.
J Psychopharmacol. 2019 Nov;33(11):1456-1466. doi: 10.1177/0269881119860666.

 

Selective serotonin 5-HT1A receptor biased agonists elicit distinct brain activation patterns: a pharmacoMRI study

Becker G, Bolbos R, Costes N, Redouté J, Newman-Tancredi A, Zimmer L
Sci Rep. 2016 May 23;6:26633. doi: 10.1038/srep26633.    

 

Pinpointing brain stem mechanisms responsible for autonomic dysfunction in Rett syndrome: therapeutic perspectives for 5-HT1A agonists

Ana P. Abdala, John Bissonnette, Adrian Newman-Tancredi,
Frontiers in Physiology 5: 205, 2014. doi: 10.3389/fphys.2014.00205   

 

A selective 5-HT1A receptor agonist improves respiration in a mouse model of Rett syndrome.

Levitt ES, Hunnicutt BJ, Knopp SJ, Williams JT, Bissonnette JM.
J Appl Physiol (1985). 2013 Dec;115(11):1626-33. Epub 2013 Oct 3.

 

Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. 

Newman-Tancredi A, Martel JC, Assié MB, Buritova J, Lauressergues E, Cosi C, Heusler P, BruinsSlot L, Colpaert F, Vacher B, Cussac D.
Br J Pharmacol. 2009 Jan;156(2):338-53. Epub 2009 Jan 12.   

 

Preferential in vivo action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors.

Lladó-Pelfort L, Assié MB, Newman-Tancredi A, Artigas F, Celada P.
Br J Pharmacol. 2010 Aug;160(8):1929-40.   

 

F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists.

Depoortère R, Auclair AL, Bardin L, Colpaert FC, Vacher B, Newman-Tancredi A.,
Eur Neuropsychopharmacol. 2010 Sep;20(9):641-54.

 

Selected Publications on Drug Discovery Program:

 

Discovery of Novel pERK1/2- or β-Arrestin-Preferring 5-HT1A Receptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile.

Sniecikowska J, Gluch-Lutwin M, Bucki A, Więckowska A, Siwek A, Jastrzebska-Wiesek M,et al.
J Med Chem. 2020 Oct 8;63(19):10946-10971. doi: 10.1021/acs.jmedchem.0c00814.

 

From Receptor Selectivity to Functional Selectivity: The Rise of Biased Agonism in 5-HT1A Receptor Drug Discovery.

Sniecikowska J, Newman-Tancredi A, Kolaczkowski M.
Curr Top Med Chem. 2019;19(26):2393-2420. doi: 10.2174/1568026619666190911122040.
 

Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT1A Receptor-Biased Agonists with Robust Antidepressant-like Activity.

Sniecikowska J, Gluch-Lutwin M, Bucki A, Więckowska A, Siwek A, Jastrzebska-Wiesek M, et al. 
J Med Chem. 2019 Mar 14;62(5):2750-2771. doi: 10.1021/acs.jmedchem.9b00062. 
 

Newsletter

Veuillez activer le javascript sur cette page pour pouvoir valider le formulaire

Follow Neurolixis on: